ALTERITY THERAPEUTICS LIMITED - Announcements

Market Cap $31.47M Add to my watchlist

Healthcare Biotechnology

Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company.... Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company’s lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson’s disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. ATH434 has been granted Orphan designation for the treatment of MSA. The Phase 2 clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage MSA.More

Announcements

Filter Results

All Price Sensitive Only

Filters [Clear]

Price Sensitive: Yes

ATH	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	30/04/24	2.04MB	Share
ATH	Alterity Receives a $3.9 million R&D Tax Incentive Refund	PRICE SENSITIVE	26/03/24	148.62KB	Share
ATH	Half Yearly Report and Accounts	PRICE SENSITIVE	28/02/24	1.17MB	Share
ATH	Alterity Therapeutics Raises $3.25 M AUD in Placement	PRICE SENSITIVE	23/02/24	181.41KB	Share
ATH	Trading Halt	PRICE SENSITIVE	22/02/24	215.18KB	Share
ATH	Phase 2 DMC Recommends Continuing Clinical Trial as Planned	PRICE SENSITIVE	06/02/24	206.35KB	Share
ATH	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/01/24	688.45KB	Share
ATH	Positive Efficacy Data for ATH434 in a Primate Model of PD	PRICE SENSITIVE	04/12/23	202.46KB	Share
ATH	Alterity Therapeutics Raises $4.8M AUD in Placement	PRICE SENSITIVE	22/11/23	232.89KB	Share
ATH	Trading Halt	PRICE SENSITIVE	20/11/23	151.71KB	Share
ATH	ATH completes enrolment in ATH434-201 Phase 2 clinical trial	PRICE SENSITIVE	08/11/23	203.7KB	Share
ATH	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	30/10/23	1.52MB	Share
ATH	Appendix 4E and Annual Report 2023	PRICE SENSITIVE	31/08/23	2.29MB	Share
ATH	Alterity Presents New Data on Multiple System Atrophy	PRICE SENSITIVE	31/08/23	208.22KB	Share
ATH	Alterity Granted New Composition of Matter Patent in Europe	PRICE SENSITIVE	23/08/23	201.79KB	Share
ATH	Alterity receives a $4.74 million R&D Tax Refund	PRICE SENSITIVE	15/08/23	127.26KB	Share
ATH	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/07/23	410.71KB	Share
ATH	Ph 2 Data Monitoring Committee Recommends Continuing Trial	PRICE SENSITIVE	26/07/23	203.82KB	Share
ATH	Investor Presentation	PRICE SENSITIVE	22/06/23	3.94MB	Share
ATH	ATH starts 2nd Phase 2 Study in Rare Parkinsonian Disorder	PRICE SENSITIVE	30/05/23	202.75KB	Share
ATH	Appendix 4C and Quarterly Cash Flow Report	PRICE SENSITIVE	27/04/23	543.38KB	Share
ATH	US patent grant and license agreement	PRICE SENSITIVE	14/03/23	202.1KB	Share
ATH	First Patient Enrolled in Europe in Phase II Clinical trial	PRICE SENSITIVE	08/03/23	202.44KB	Share
ATH	Half Yearly Report and Accounts	PRICE SENSITIVE	28/02/23	838.3KB	Share
ATH	Regulatory approval for Phase II trial in France and Austria	PRICE SENSITIVE	16/02/23	203.83KB	Share
ATH	Appendix 4C and Quarterly Cash Flow Report	PRICE SENSITIVE	31/01/23	587.2KB	Share
ATH	ATH434 Clinical Trial Launched in Italy	PRICE SENSITIVE	25/01/23	222.39KB	Share
ATH	ATH434 clinical trial launched in the US	PRICE SENSITIVE	09/01/23	224.03KB	Share
ATH	New US patent for compounds to treat neurodegeneration	PRICE SENSITIVE	29/12/22	200.25KB	Share
ATH	Appendix 4C and Quarterly Cash Flow Report	PRICE SENSITIVE	28/10/22	661.29KB	Share
ATH	ATH434 Clinical Trial launched in Australia	PRICE SENSITIVE	13/10/22	221.72KB	Share
ATH	US FDA Approval for IND Application for ATH434 for MSA	PRICE SENSITIVE	20/09/22	214.31KB	Share
ATH	Appendix 4E & Annual Report 2022	PRICE SENSITIVE	31/08/22	1.7MB	Share
ATH	ATH434 Phase 2 clinical launched in Europe	PRICE SENSITIVE	25/08/22	220.13KB	Share
ATH	Appendix 4C and Quarterly Cash Flow Report	PRICE SENSITIVE	22/07/22	698.61KB	Share
ATH	First Patient dosed in ATH434 Phase 2 Clinical Trial	PRICE SENSITIVE	06/07/22	202.37KB	Share
ATH	Alterity receives a $4.1 million R&D Tax Refund	PRICE SENSITIVE	30/06/22	97.77KB	Share
ATH	Regulatory Approval to Proceed with Phase 2 Trial in Italy	PRICE SENSITIVE	23/06/22	201.49KB	Share
ATH	Alterity Launches ATH434 Phase 2 Clinical Trial	PRICE SENSITIVE	02/06/22	248.75KB	Share
ATH	Appendix 4C and Quarterly Cash Flow Report	PRICE SENSITIVE	29/04/22	1.38MB	Share
ATH	UK Regulatory Authorisation to Proceed with Phase 2 Trial	PRICE SENSITIVE	27/04/22	226.1KB	Share
ATH	Investor Presentation	PRICE SENSITIVE	07/03/22	4.98MB	Share
ATH	Half Yearly Report and Accounts	PRICE SENSITIVE	28/02/22	387.79KB	Share
ATH	New publication shows ATH434 rescues neurons in MSA model	PRICE SENSITIVE	28/01/22	270.75KB	Share
ATH	Appendix 4C and Quarterly Cash Flow Report	PRICE SENSITIVE	27/01/22	421.77KB	Share
ATH	Response to ASX Query	PRICE SENSITIVE	13/01/22	217.88KB	Share
ATH	New US Patent for Compounds to Treat Neurodegeneration	PRICE SENSITIVE	06/01/22	272.5KB	Share
ATH	First Regulatory Authorization to Proceed with Phase 2 Trial	PRICE SENSITIVE	14/12/21	251.98KB	Share
ATH	ATH Annual General Meeting Presentation	PRICE SENSITIVE	12/11/21	3.45MB	Share
ATH	Chairman's Address 2021 Annual General Meeting	PRICE SENSITIVE	12/11/21	200.85KB	Share
ATH	New Data Advance ATH434 as Neurodegeneration treatment	PRICE SENSITIVE	04/11/21	262.43KB	Share
ATH	Appendix 4C and Quarterly Cash Flow Report	PRICE SENSITIVE	29/10/21	1.81MB	Share
ATH	Expanded ATH434 Phase 2 Clinical Development Program	PRICE SENSITIVE	19/10/21	281.81KB	Share
ATH	Form 20-F	PRICE SENSITIVE	03/09/21	776.23KB	Share
ATH	Appendix 4E & Annual Report 2021	PRICE SENSITIVE	01/09/21	2.76MB	Share
ATH	New US Patent Expands Neurodegeneration Treatment Portfolio	PRICE SENSITIVE	04/08/21	250.2KB	Share
ATH	Appendix 4C and Quarterly Cash Flow Report	PRICE SENSITIVE	30/07/21	411.12KB	Share
ATH	New Publication Demonstrates ATH434 is Neuroprotective	PRICE SENSITIVE	15/07/21	348.84KB	Share
ATH	New US patent targeting major neurodegenerative diseases	PRICE SENSITIVE	01/07/21	233.13KB	Share
ATH	EU Regulatory Guidance for ATH434 Phase 2 Clinical Trial	PRICE SENSITIVE	23/06/21	212.4KB	Share
ATH	Investor Presentation	PRICE SENSITIVE	17/06/21	2.01MB	Share
ATH	Appendix 4C and Quarterly Cash Flow Report	PRICE SENSITIVE	29/04/21	418.29KB	Share
ATH	ATH434 protects brain cells and improves motor function	PRICE SENSITIVE	21/04/21	220.99KB	Share
ATH	Alterity to present at Global Life Science Conference	PRICE SENSITIVE	10/03/21	1.79MB	Share
ATH	Half Yearly Report and Accounts	PRICE SENSITIVE	25/02/21	373.54KB	Share
ATH	Michael J Fox grant for Parkinson's research on ATH434	PRICE SENSITIVE	09/02/21	192.69KB	Share
ATH	Appendix 4C and Quarterly Cash Flow Report	PRICE SENSITIVE	28/01/21	338.79KB	Share
ATH	Alterity participates in JP Morgan healthcare conference	PRICE SENSITIVE	11/01/21	201KB	Share
ATH	Dr David Stamler Appointed CEO	PRICE SENSITIVE	07/01/21	258.79KB	Share
ATH	Form F-3	PRICE SENSITIVE	24/12/20	300.42KB	Share
ATH	New commercial opportunity for PBT2	PRICE SENSITIVE	21/12/20	288.04KB	Share
ATH	Alterity presents at Finance News Network	PRICE SENSITIVE	02/12/20	756.28KB	Share
ATH	Prospectus filed pursuant to SEC Rule 424(b)(3)	PRICE SENSITIVE	24/11/20	261.13KB	Share
ATH	ATH Annual General Meeting Presentation	PRICE SENSITIVE	18/11/20	1.83MB	Share
ATH	Chairman's Address 2020 Annual General Meeting	PRICE SENSITIVE	18/11/20	235.47KB	Share
ATH	US patent for next generation neurodegenerative diseases	PRICE SENSITIVE	16/11/20	180.99KB	Share
ATH	Appendix 4C and Quarterly Cash Flow Report	PRICE SENSITIVE	30/10/20	353.74KB	Share
ATH	MSA patients enrolled in bioMUSE Study	PRICE SENSITIVE	27/10/20	184.03KB	Share
ATH	Alterity completes Placement Tranche 1 raising $10M	PRICE SENSITIVE	23/10/20	205.61KB	Share
ATH	Alterity raises $35M in placement to institutional investors	PRICE SENSITIVE	16/10/20	234.89KB	Share
ATH	Trading Halt	PRICE SENSITIVE	12/10/20	164.99KB	Share
ATH	Form 20-F	PRICE SENSITIVE	16/09/20	2.41MB	Share
ATH	Company update on Annual Report 2020	PRICE SENSITIVE	09/09/20	177.51KB	Share
ATH	Preliminary Final Report	PRICE SENSITIVE	31/08/20	513.84KB	Share
ATH	New data independently confirms safety profile of ATH434	PRICE SENSITIVE	04/08/20	229.39KB	Share
ATH	Appendix 4C and Quarterly Cash Flow Report	PRICE SENSITIVE	30/07/20	375.42KB	Share
ATH	Response to ASX Price Query	PRICE SENSITIVE	01/07/20	1003.48KB	Share
ATH	Pause in Trading	PRICE SENSITIVE	01/07/20	115.98KB	Share
ATH	Meeting with US FDA provides development path for ATH434	PRICE SENSITIVE	30/06/20	210.21KB	Share
ATH	Presentation on ATH434 to American Academy of Neurology	PRICE SENSITIVE	21/05/20	203.75KB	Share
ATH	Appendix 4C and Quarterly Update	PRICE SENSITIVE	30/04/20	345.52KB	Share
ATH	NASDAQ Temporary Relief	PRICE SENSITIVE	22/04/20	193.8KB	Share
ATH	Half Yearly Report and Accounts	PRICE SENSITIVE	27/02/20	432.22KB	Share
ATH	NASDAQ Non-Compliance Notice Received	PRICE SENSITIVE	07/02/20	217.47KB	Share
ATH	Appendix 4C - quarterly	PRICE SENSITIVE	31/01/20	372.04KB	Share
ATH	Alterity receives a $4.8 million R&D Tax Incentive Refund	PRICE SENSITIVE	15/01/20	150.88KB	Share
ATH	European Orphan Designation granted for PBT434 for MSA	PRICE SENSITIVE	14/01/20	154.13KB	Share
ATH	AGM Presentation 2019	PRICE SENSITIVE	26/11/19	776.76KB	Share
ATH	Chairman's Address to Shareholders	PRICE SENSITIVE	26/11/19	155.78KB	Share
ATH	Lead drug candidate receives positive opinion from EMA	PRICE SENSITIVE	18/11/19	153.3KB	Share

ATH Quarterly Activities/Appendix 4C Cash Flow Report
30/04/24	PRICE SENSITIVE	2.04MB	Share
ATH Alterity Receives a $3.9 million R&D Tax Incentive Refund
26/03/24	PRICE SENSITIVE	148.62KB	Share
ATH Half Yearly Report and Accounts
28/02/24	PRICE SENSITIVE	1.17MB	Share
ATH Alterity Therapeutics Raises $3.25 M AUD in Placement
23/02/24	PRICE SENSITIVE	181.41KB	Share
ATH Trading Halt
22/02/24	PRICE SENSITIVE	215.18KB	Share
ATH Phase 2 DMC Recommends Continuing Clinical Trial as Planned
06/02/24	PRICE SENSITIVE	206.35KB	Share
ATH Quarterly Activities/Appendix 4C Cash Flow Report
31/01/24	PRICE SENSITIVE	688.45KB	Share
ATH Positive Efficacy Data for ATH434 in a Primate Model of PD
04/12/23	PRICE SENSITIVE	202.46KB	Share
ATH Alterity Therapeutics Raises $4.8M AUD in Placement
22/11/23	PRICE SENSITIVE	232.89KB	Share
ATH Trading Halt
20/11/23	PRICE SENSITIVE	151.71KB	Share
ATH ATH completes enrolment in ATH434-201 Phase 2 clinical trial
08/11/23	PRICE SENSITIVE	203.7KB	Share
ATH Quarterly Activities/Appendix 4C Cash Flow Report
30/10/23	PRICE SENSITIVE	1.52MB	Share
ATH Appendix 4E and Annual Report 2023
31/08/23	PRICE SENSITIVE	2.29MB	Share
ATH Alterity Presents New Data on Multiple System Atrophy
31/08/23	PRICE SENSITIVE	208.22KB	Share
ATH Alterity Granted New Composition of Matter Patent in Europe
23/08/23	PRICE SENSITIVE	201.79KB	Share
ATH Alterity receives a $4.74 million R&D Tax Refund
15/08/23	PRICE SENSITIVE	127.26KB	Share
ATH Quarterly Activities/Appendix 4C Cash Flow Report
31/07/23	PRICE SENSITIVE	410.71KB	Share
ATH Ph 2 Data Monitoring Committee Recommends Continuing Trial
26/07/23	PRICE SENSITIVE	203.82KB	Share
ATH Investor Presentation
22/06/23	PRICE SENSITIVE	3.94MB	Share
ATH ATH starts 2nd Phase 2 Study in Rare Parkinsonian Disorder
30/05/23	PRICE SENSITIVE	202.75KB	Share
ATH Appendix 4C and Quarterly Cash Flow Report
27/04/23	PRICE SENSITIVE	543.38KB	Share
ATH US patent grant and license agreement
14/03/23	PRICE SENSITIVE	202.1KB	Share
ATH First Patient Enrolled in Europe in Phase II Clinical trial
08/03/23	PRICE SENSITIVE	202.44KB	Share
ATH Half Yearly Report and Accounts
28/02/23	PRICE SENSITIVE	838.3KB	Share
ATH Regulatory approval for Phase II trial in France and Austria
16/02/23	PRICE SENSITIVE	203.83KB	Share
ATH Appendix 4C and Quarterly Cash Flow Report
31/01/23	PRICE SENSITIVE	587.2KB	Share
ATH ATH434 Clinical Trial Launched in Italy
25/01/23	PRICE SENSITIVE	222.39KB	Share
ATH ATH434 clinical trial launched in the US
09/01/23	PRICE SENSITIVE	224.03KB	Share
ATH New US patent for compounds to treat neurodegeneration
29/12/22	PRICE SENSITIVE	200.25KB	Share
ATH Appendix 4C and Quarterly Cash Flow Report
28/10/22	PRICE SENSITIVE	661.29KB	Share
ATH ATH434 Clinical Trial launched in Australia
13/10/22	PRICE SENSITIVE	221.72KB	Share
ATH US FDA Approval for IND Application for ATH434 for MSA
20/09/22	PRICE SENSITIVE	214.31KB	Share
ATH Appendix 4E & Annual Report 2022
31/08/22	PRICE SENSITIVE	1.7MB	Share
ATH ATH434 Phase 2 clinical launched in Europe
25/08/22	PRICE SENSITIVE	220.13KB	Share
ATH Appendix 4C and Quarterly Cash Flow Report
22/07/22	PRICE SENSITIVE	698.61KB	Share
ATH First Patient dosed in ATH434 Phase 2 Clinical Trial
06/07/22	PRICE SENSITIVE	202.37KB	Share
ATH Alterity receives a $4.1 million R&D Tax Refund
30/06/22	PRICE SENSITIVE	97.77KB	Share
ATH Regulatory Approval to Proceed with Phase 2 Trial in Italy
23/06/22	PRICE SENSITIVE	201.49KB	Share
ATH Alterity Launches ATH434 Phase 2 Clinical Trial
02/06/22	PRICE SENSITIVE	248.75KB	Share
ATH Appendix 4C and Quarterly Cash Flow Report
29/04/22	PRICE SENSITIVE	1.38MB	Share
ATH UK Regulatory Authorisation to Proceed with Phase 2 Trial
27/04/22	PRICE SENSITIVE	226.1KB	Share
ATH Investor Presentation
07/03/22	PRICE SENSITIVE	4.98MB	Share
ATH Half Yearly Report and Accounts
28/02/22	PRICE SENSITIVE	387.79KB	Share
ATH New publication shows ATH434 rescues neurons in MSA model
28/01/22	PRICE SENSITIVE	270.75KB	Share
ATH Appendix 4C and Quarterly Cash Flow Report
27/01/22	PRICE SENSITIVE	421.77KB	Share
ATH Response to ASX Query
13/01/22	PRICE SENSITIVE	217.88KB	Share
ATH New US Patent for Compounds to Treat Neurodegeneration
06/01/22	PRICE SENSITIVE	272.5KB	Share
ATH First Regulatory Authorization to Proceed with Phase 2 Trial
14/12/21	PRICE SENSITIVE	251.98KB	Share
ATH ATH Annual General Meeting Presentation
12/11/21	PRICE SENSITIVE	3.45MB	Share
ATH Chairman's Address 2021 Annual General Meeting
12/11/21	PRICE SENSITIVE	200.85KB	Share
ATH New Data Advance ATH434 as Neurodegeneration treatment
04/11/21	PRICE SENSITIVE	262.43KB	Share
ATH Appendix 4C and Quarterly Cash Flow Report
29/10/21	PRICE SENSITIVE	1.81MB	Share
ATH Expanded ATH434 Phase 2 Clinical Development Program
19/10/21	PRICE SENSITIVE	281.81KB	Share
ATH Form 20-F
03/09/21	PRICE SENSITIVE	776.23KB	Share
ATH Appendix 4E & Annual Report 2021
01/09/21	PRICE SENSITIVE	2.76MB	Share
ATH New US Patent Expands Neurodegeneration Treatment Portfolio
04/08/21	PRICE SENSITIVE	250.2KB	Share
ATH Appendix 4C and Quarterly Cash Flow Report
30/07/21	PRICE SENSITIVE	411.12KB	Share
ATH New Publication Demonstrates ATH434 is Neuroprotective
15/07/21	PRICE SENSITIVE	348.84KB	Share
ATH New US patent targeting major neurodegenerative diseases
01/07/21	PRICE SENSITIVE	233.13KB	Share
ATH EU Regulatory Guidance for ATH434 Phase 2 Clinical Trial
23/06/21	PRICE SENSITIVE	212.4KB	Share
ATH Investor Presentation
17/06/21	PRICE SENSITIVE	2.01MB	Share
ATH Appendix 4C and Quarterly Cash Flow Report
29/04/21	PRICE SENSITIVE	418.29KB	Share
ATH ATH434 protects brain cells and improves motor function
21/04/21	PRICE SENSITIVE	220.99KB	Share
ATH Alterity to present at Global Life Science Conference
10/03/21	PRICE SENSITIVE	1.79MB	Share
ATH Half Yearly Report and Accounts
25/02/21	PRICE SENSITIVE	373.54KB	Share
ATH Michael J Fox grant for Parkinson's research on ATH434
09/02/21	PRICE SENSITIVE	192.69KB	Share
ATH Appendix 4C and Quarterly Cash Flow Report
28/01/21	PRICE SENSITIVE	338.79KB	Share
ATH Alterity participates in JP Morgan healthcare conference
11/01/21	PRICE SENSITIVE	201KB	Share
ATH Dr David Stamler Appointed CEO
07/01/21	PRICE SENSITIVE	258.79KB	Share
ATH Form F-3
24/12/20	PRICE SENSITIVE	300.42KB	Share
ATH New commercial opportunity for PBT2
21/12/20	PRICE SENSITIVE	288.04KB	Share
ATH Alterity presents at Finance News Network
02/12/20	PRICE SENSITIVE	756.28KB	Share
ATH Prospectus filed pursuant to SEC Rule 424(b)(3)
24/11/20	PRICE SENSITIVE	261.13KB	Share
ATH ATH Annual General Meeting Presentation
18/11/20	PRICE SENSITIVE	1.83MB	Share
ATH Chairman's Address 2020 Annual General Meeting
18/11/20	PRICE SENSITIVE	235.47KB	Share
ATH US patent for next generation neurodegenerative diseases
16/11/20	PRICE SENSITIVE	180.99KB	Share
ATH Appendix 4C and Quarterly Cash Flow Report
30/10/20	PRICE SENSITIVE	353.74KB	Share
ATH MSA patients enrolled in bioMUSE Study
27/10/20	PRICE SENSITIVE	184.03KB	Share
ATH Alterity completes Placement Tranche 1 raising $10M
23/10/20	PRICE SENSITIVE	205.61KB	Share
ATH Alterity raises $35M in placement to institutional investors
16/10/20	PRICE SENSITIVE	234.89KB	Share
ATH Trading Halt
12/10/20	PRICE SENSITIVE	164.99KB	Share
ATH Form 20-F
16/09/20	PRICE SENSITIVE	2.41MB	Share
ATH Company update on Annual Report 2020
09/09/20	PRICE SENSITIVE	177.51KB	Share
ATH Preliminary Final Report
31/08/20	PRICE SENSITIVE	513.84KB	Share
ATH New data independently confirms safety profile of ATH434
04/08/20	PRICE SENSITIVE	229.39KB	Share
ATH Appendix 4C and Quarterly Cash Flow Report
30/07/20	PRICE SENSITIVE	375.42KB	Share
ATH Response to ASX Price Query
01/07/20	PRICE SENSITIVE	1003.48KB	Share
ATH Pause in Trading
01/07/20	PRICE SENSITIVE	115.98KB	Share
ATH Meeting with US FDA provides development path for ATH434
30/06/20	PRICE SENSITIVE	210.21KB	Share
ATH Presentation on ATH434 to American Academy of Neurology
21/05/20	PRICE SENSITIVE	203.75KB	Share
ATH Appendix 4C and Quarterly Update
30/04/20	PRICE SENSITIVE	345.52KB	Share
ATH NASDAQ Temporary Relief
22/04/20	PRICE SENSITIVE	193.8KB	Share
ATH Half Yearly Report and Accounts
27/02/20	PRICE SENSITIVE	432.22KB	Share
ATH NASDAQ Non-Compliance Notice Received
07/02/20	PRICE SENSITIVE	217.47KB	Share
ATH Appendix 4C - quarterly
31/01/20	PRICE SENSITIVE	372.04KB	Share
ATH Alterity receives a $4.8 million R&D Tax Incentive Refund
15/01/20	PRICE SENSITIVE	150.88KB	Share
ATH European Orphan Designation granted for PBT434 for MSA
14/01/20	PRICE SENSITIVE	154.13KB	Share
ATH AGM Presentation 2019
26/11/19	PRICE SENSITIVE	776.76KB	Share
ATH Chairman's Address to Shareholders
26/11/19	PRICE SENSITIVE	155.78KB	Share
ATH Lead drug candidate receives positive opinion from EMA
18/11/19	PRICE SENSITIVE	153.3KB	Share

REFRESH

1 2

(20min delay)
Last 0.6¢		Change 0.000(0.00%)		Mkt cap ! $31.47M

Open	High	Low	Value	Volume
0.6¢	0.6¢	0.6¢	$9.573K	1.633M

Buyers (Bids)

No.	Vol.	Price($)
70	66663606	0.5¢

Sellers (Offers)

Price($)	Vol.	No.
0.6¢	12189391	9

View Market Depth

No.	Vol.	Price($)
70	66663606	0.005
53	59859382	0.004
49	47623315	0.003
17	33693014	0.002
12	93870101	0.001

Price($)	Vol.	No.
0.006	12189391	9
0.007	21612749	17
0.008	16761310	22
0.009	11788078	12
0.010	2540594	8

Last trade - 16.10pm 08/05/2024 (20 minute delay)


Last 0.6¢		Change 0.000 ( 0.00 %)
Open	High	Low	Volume
0.6¢	0.6¢	0.6¢	363313
Last updated 15.59pm 08/05/2024 ?

ATH (ASX) Chart

ALTERITY THERAPEUTICS LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories